Tesamorelin is the only FDA-approved GHRH analog — approved as Egrifta for HIV-associated visceral fat — and has the strongest clinical evidence of any GH secretagogue for reducing abdominal fat while improving lipid profiles and preserving lean mass.
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.
Overview
Tesamorelin (TH9507) is a synthetic analogue of endogenous GHRH with a trans-3-hexenoic acid modification added to its N-terminus, which dramatically increases its enzymatic stability without altering its receptor specificity. It was developed by Theratechnologies and received FDA approval in 2010 as Egrifta specifically for HIV-associated lipodystrophy — a condition characterized by pathological visceral fat accumulation in HIV patients on antiretroviral therapy. Its approval was based on robust Phase 3 clinical trial data showing consistent, sustained visceral adipose tissue (VAT) reduction across multiple trials — evidence quality that surpasses most other GH-secretagogue research compounds significantly.
Mechanism of Action
Tesamorelin binds to the GHRH receptor on anterior pituitary somatotrophs with the same mechanism as endogenous GHRH, triggering cAMP-mediated GH synthesis and release. Unlike continuous GHRH infusion (which causes receptor desensitization), daily subcutaneous injection produces a pulsatile GH pattern that preserves the natural feedback loop. The resulting GH elevation drives IGF-1 production, which mediates most of tesamorelin's downstream metabolic effects: increased lipolysis in visceral adipocytes, improved fatty acid oxidation, favorable shifts in lipid profiles (reduced triglycerides, improved HDL), and preservation of lean body mass. Notably, the IGF-1 elevation is within physiological range, meaning the benefits of GH axis stimulation are achieved without supraphysiological IGF-1 that carries theoretical proliferative risks.
Key Research
Tesamorelin has the most extensive clinical evidence base of any non-approved-GH secretagogue. Phase 3 LIPO trials (N=272 and N=391) demonstrated statistically significant 15.2% and 10.5% reductions in visceral adipose tissue at 26 weeks vs placebo. A 52-week extension study showed continued VAT reduction with maintained treatment. Improvements in triglycerides, non-HDL cholesterol, and inflammatory markers (CRP) were documented alongside fat loss. Cognitive benefits were demonstrated in an independent study at UCSF — tesamorelin significantly improved verbal memory and executive function in mild cognitive impairment over 20 weeks. The drug received FDA approval in 2010; follow-on clinical research in non-HIV metabolic syndrome continues.
The FDA-approved dose is 2 mg SC once daily for HIV-associated lipodystrophy. In non-HIV metabolic research contexts, 1–2 mg SC daily (fasted morning, 30 minutes before eating) is the standard protocol. Fasted injection is critical — insulin blunts GH release and reduces efficacy. Results on visceral fat are measurable by 12 weeks with maximum effect at 26 weeks. Discontinuation reverses the fat loss over time — ongoing use is required for sustained benefit. Pairs well with Ipamorelin for GHRH + GHRP synergistic GH amplification.
Visceral Fat Reduction Protocol: Tesamorelin 1–2 mg SC daily (fasted morning) for 26+ weeks. Can be combined with Ipamorelin 200 mcg SC pre-bed for GHRH + GHRP synergy. Metabolic Syndrome Stack: Tesamorelin 1 mg + MOTS-c 5 mg 3x weekly + BPC-157 500 mcg oral daily for visceral fat, mitochondrial function, and gut-axis optimization. Cognitive Health Protocol: Tesamorelin 1 mg SC daily for 20 weeks, based on published UCSF cognitive benefits data.
Reported Side Effects
Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
Tesamorelin's most common side effects are injection site reactions (pain, redness, swelling — in approximately 25% of subjects), peripheral edema (water retention, particularly in the ankles), arthralgia (joint pain), and myalgia. These are consistent with GH-axis stimulation and are generally mild. Glucose and insulin should be monitored — GH can cause transient insulin resistance and tesamorelin may worsen glycemic control in pre-diabetic or diabetic individuals. IGF-1 should be monitored at baseline and every 6 months — if levels rise above normal range, dose reduction is indicated. Contraindicated in active malignancy.
Storage & Handling
Store tesamorelin at 2–8°C. Protect from light and do not freeze. The Egrifta formulation is supplied as a lyophilized powder with a diluent; reconstitute immediately before use and inject within 3 hours per prescribing information. Research-grade lyophilized tesamorelin: store at 2–8°C, reconstitute with bacteriostatic water, and use within 21–28 days. Do not freeze reconstituted solution. Inject in the morning, rotating injection sites within the abdomen.
Age Verification Required
This site contains information about research peptides intended for adults 21 and older. By continuing you confirm you are of legal age in your jurisdiction.
By confirming below, you agree that you are at least 21 years of age and legally able to access this content in your jurisdiction.
Access Restricted
We're sorry, but you must be at least 21 years of age to access this site. This content contains research information intended for adults only.
Research Disclaimer
RESEARCH USE ONLY: All information, tools, and resources on Peptide Oracle are for educational and research purposes only.
Not Medical Advice: Nothing on this website constitutes medical advice, diagnosis, or treatment. This site does not replace professional medical consultation.
Not for Human Consumption: Peptides discussed are for laboratory and research purposes only. They are not approved for human use, consumption, or self-administration.
No Therapeutic Claims: We make no claims regarding the safety, efficacy, or therapeutic benefits of any peptides or compounds discussed.
Legal Compliance: You are responsible for compliance with all applicable local, state, and federal laws regarding peptide research and acquisition.
Limitation of Liability: Peptide Oracle assumes no liability for any damages resulting from use of information provided on this site.
Saved for 30 days. Reset by clearing browser data.
We use cookies to improve your experience and analyse site usage. By clicking Accept All you consent to our use of cookies. Cookie Policy
